Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351). Issue 6 (8th April 2021) - Salhotra, Amandeep; Aribi, Ahmed; Ngo, Dat; Zhang, Jianying; Sandhu, Karamjeet; Al‐Malki, Monzr; Ali, Haris; Koller, Paul; Arslan, Shukaib; Budde, Elizabeth; Khaled, Samer; Dadwal, Sanjeet; et al.